Clinuvel Pharmaceuticals (ASX:CUV) Inventory Turnover: 0.25 (As of Dec. 2025)

What is Clinuvel Pharmaceuticals Inventory Turnover?

Clinuvel Pharmaceuticals ASX:CUV +0.78% 86 Inventory Turnover is 0.25 as of Dec. 2025. GuruFocus rates ASX:CUV with a GF Score™ of 86/100 and a GF Value™ of A$17.74 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Clinuvel Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2025 was A$2.14 Mil. Clinuvel Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2025 was A$8.62 Mil. Clinuvel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.25.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Clinuvel Pharmaceuticals's Days Inventory for the six months ended in Dec. 2025 was 733.83.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Clinuvel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.23.

Clinuvel Pharmaceuticals (ASX:CUV) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Clinuvel Pharmaceuticals's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2025 )	/	Cost of Goods Sold (Q: Dec. 2025 )	*	Days in Period
	=	8.617	/	2.143	*	365 / 2
	=	733.83

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Clinuvel Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	8.617	/	36.931
	=	0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Clinuvel Pharmaceuticals Inventory Turnover Related Terms

Clinuvel Pharmaceuticals Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Inventory Turnover can be seen below:

Clinuvel Pharmaceuticals Inventory Turnover Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Inventory Turnover

Get a 7-Day Free Trial

2.11

4.18

1.55

1.00

1.63

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Inventory Turnover	Get a 7-Day Free Trial															0.10	0.78	0.13	1.59	0.25

86GF Score

Clinuvel Pharmaceuticals Ltd ASX:CUV

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Clinuvel Pharmaceuticals Inventory Turnover Calculation

Clinuvel Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Jun. 2025 is calculated as

	Inventory Turnover (A: Jun. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Jun. 2025 )	/ (	(Total Inventories (A: Jun. 2024 )	+	Total Inventories (A: Jun. 2025 ))	/	count )
=	15.881	/ (	(10.627	+	8.821)	/	2 )
=	15.881	/	9.724
=	1.63

Clinuvel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

	Inventory Turnover (Q: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Dec. 2025 )	/ (	(Total Inventories (Q: Jun. 2025 )	+	Total Inventories (Q: Dec. 2025 ))	/	count )
=	2.143	/ (	(8.821	+	8.413)	/	2 )
=	2.143	/	8.617
=	0.25

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.25 mean?

Clinuvel Pharmaceuticals (ASX:CUV) has a Inventory Turnover of 0.25 as of Dec. 2025. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Clinuvel Pharmaceuticals and its competitors.

Is Clinuvel Pharmaceuticals' Inventory Turnover too high?

Clinuvel Pharmaceuticals' current Inventory Turnover is 0.25. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Clinuvel Pharmaceuticals' Inventory Turnover compare to VRTX and REGN?

Clinuvel Pharmaceuticals' Inventory Turnover of 0.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Inventory Turnover is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Clinuvel Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.74, compared to a current price of A$10.29 — trading 42% below its estimated fair value. The current Inventory Turnover is 0.25. Clinuvel Pharmaceuticals' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Inventory Turnover is 0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.29 is trading 42% below its estimated GF Value™ of A$17.74. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

Inventory Turnover: 0.25
GF Value™: A$17.74 vs. price of A$10.29 (42% below fair value)
GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:RAC ASX:CU6 ASX:TTX ASX:SPL ASX:OCC ASX:ATH ASX:ACW ASX:RCE ASX:DXB ASX:ILA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CLVLY:USA CLVLF:USA UR9:Germany

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

86GF Score

Get the complete analysis for ASX:CUV

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.29

Price

A$17.74

GF Value

View ASX:CUV Analysis

See Inventory Turnover data for all stocks →